TY - JOUR
T1 - Cancer of the corpus uteri
AU - Amant, Frédéric
AU - Mirza, Mansoor Raza
AU - Koskas, Martin
AU - Creutzberg, Carien L.
PY - 2018
Y1 - 2018
N2 - Endometrial cancer is the most common gynecological malignancy in high-income countries. Although the overall prognosis is relatively good, high-grade endometrial cancers have a tendency to recur. Recurrence needs to be prevented since the prognosis for recurrent endometrial cancer is dismal. Treatment tailored to tumor biology is the optimal strategy to balance treatment efficacy against toxicity. Standard treatment consists of hysterectomy and bilateral salpingo-oophorectomy. Lymphadenectomy (with ongoing studies of sentinel node biopsy) enables identification of lymph node positive patients who need adjuvant treatment, including radiotherapy and chemotherapy. Adjuvant radiotherapy is used for Stage I–II patients with high-risk factors and Stage III lymph node negative patients. In advanced disease, a combination of surgery to no residual disease and chemotherapy results in the best outcome. Surgery for recurrent disease is only advocated in patients with a good performance status with a relatively long disease-free interval.
AB - Endometrial cancer is the most common gynecological malignancy in high-income countries. Although the overall prognosis is relatively good, high-grade endometrial cancers have a tendency to recur. Recurrence needs to be prevented since the prognosis for recurrent endometrial cancer is dismal. Treatment tailored to tumor biology is the optimal strategy to balance treatment efficacy against toxicity. Standard treatment consists of hysterectomy and bilateral salpingo-oophorectomy. Lymphadenectomy (with ongoing studies of sentinel node biopsy) enables identification of lymph node positive patients who need adjuvant treatment, including radiotherapy and chemotherapy. Adjuvant radiotherapy is used for Stage I–II patients with high-risk factors and Stage III lymph node negative patients. In advanced disease, a combination of surgery to no residual disease and chemotherapy results in the best outcome. Surgery for recurrent disease is only advocated in patients with a good performance status with a relatively long disease-free interval.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85054760516&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30306580
U2 - https://doi.org/10.1002/ijgo.12612
DO - https://doi.org/10.1002/ijgo.12612
M3 - Article
C2 - 30306580
SN - 0020-7292
VL - 143
SP - 37
EP - 50
JO - International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
JF - International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ER -